

1 Increased rates of genomic mutation in a biofilm co-  
2 culture model of *Pseudomonas aeruginosa* and  
3 *Staphylococcus aureus*

4

5 Frapwell C.J.<sup>1</sup>, Howlin R.P.<sup>1,2,3,4</sup>, Soren O.<sup>1</sup>, McDonagh B.T.<sup>1,5</sup>, Duignan C.M.<sup>1,2,3</sup>,  
6 Allan R.N.<sup>1,2,3,4</sup>, Horswill A.R.<sup>6</sup>, Stoodley P.<sup>7,8</sup>, Hu Y.<sup>9,10</sup>, Coates A.R.M.<sup>9,10</sup>,  
7 Webb J. S.<sup>1,2,3,4,\*</sup>

8

- 9 1. Centre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK  
10 2. NIHR Southampton Respiratory Biomedical Research Centre, Southampton SO16 6YD, UK  
11 3. University Hospital Southampton NHS Foundation Trust, Southampton, SO16, 6YD, UK  
12 4. Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK  
13 5. Biosafety, Air and Water Microbiology Group, Public Health England, Porton Down, UK  
14 6. Department of Immunology and Microbiology, The University of Colorado, School of  
15 Medicine, Aurora, USA  
16 7. National Centre for Advanced Tribology at Southampton (nCATS), Mechanical Engineering,  
17 University of Southampton, Southampton SO17 1BJ, UK  
18 8. Depts. Microbial Infection and Immunity and Orthopaedics, The Ohio State University,  
19 Columbus, OH 43210-2210, USA  
20 9. Institute of Infection and Immunity, St George's, University of London, Cranmer Terrace,  
21 London, UK  
22 10. Helderby Therapeutics Group plc, London, United Kingdom  
23

24 \* corresponding author

## 25 Abstract

26 Biofilms are major contributors to disease chronicity and are typically multi-species in  
27 nature. *Pseudomonas aeruginosa* and *Staphylococcus aureus* are leading causes of  
28 morbidity and mortality in a variety of chronic diseases but current *in vitro* dual-  
29 species biofilms models involving these pathogens are limited by short co-culture  
30 times (24 to 48 hours). Here, we describe the establishment of a stable (240 hour)  
31 co-culture biofilm model of *P. aeruginosa* and *S. aureus* that is reproducible and  
32 more representative of chronic disease.

33

34 The ability of two *P. aeruginosa* strains, (PAO1 and a cystic fibrosis isolate, PA21),  
35 to form co-culture biofilms with *S. aureus* was investigated. Co-culture was stable for  
36 longer periods using *P. aeruginosa* PA21 and *S. aureus* viability within the model  
37 improved in the presence of exogenous hemin. Biofilm co-culture was associated  
38 with increased tolerance of *P. aeruginosa* to tobramycin and increased susceptibility  
39 of *S. aureus* to tobramycin and a novel antimicrobial, HT61, previously shown to be  
40 more effective against non-dividing cultures of *Staphylococcal spp.* Biofilm growth  
41 was also associated with increased short-term mutation rates; 10-fold for *P.*  
42 *aeruginosa* and 500-fold for *S. aureus*.

43

44 By describing a reproducible 240 hour co-culture biofilm model of *P. aeruginosa* and  
45 *S. aureus*, we have shown that interspecies interactions between these organisms  
46 may influence short-term mutation rates and evolution, which could be of importance  
47 in understanding the adaptive processes that lead to the development of  
48 antimicrobial resistance.

49

50

51

52

53

54

## 55 Introduction

56 Treatment of bacterial infections is often complicated by the presence of biofilms;  
57 communities of bacteria characterised by a heterogeneous composition and  
58 tolerance to antimicrobial treatment<sup>1,2</sup>. Tolerance towards antimicrobial compounds  
59 has further been linked with the emergence of mutations that confer AMR in  
60 planktonic cultures<sup>3</sup> so it is possible that biofilm-mediated tolerance mechanisms  
61 could contribute similarly. Therefore, the development of relevant biofilm models is  
62 vital to understanding the interplay between biofilm tolerance mechanisms and the  
63 emergence of AMR.

64

65 Two bacterial species that are commonly implicated in biofilm infections are  
66 *Pseudomonas aeruginosa* and *Staphylococcus aureus*. In cystic fibrosis co-infection  
67 is associated with increased inflammation and reduced therapeutic outcomes for  
68 patients<sup>4</sup>, and in chronic wounds they are the most commonly co-isolated bacterial  
69 species and linked to poorer clinical outcomes<sup>5</sup>. However, whether the two species  
70 are co-localised or spatially partitioned remains a point of contention; in part because  
71 *in vitro* studies suggest that the relationship of these two bacteria is often  
72 antagonistic in nature<sup>6-8</sup>.

73

74 Although it is widely recognised that *in vivo* biofilms are often composed of a  
75 multispecies consortium, the majority of *in vitro* biofilm studies fail to reflect this,  
76 focusing on single species. Previous models investigating co-culture of *P.*  
77 *aeruginosa* and *S. aureus* *in vitro* have frequently observed that *P. aeruginosa*  
78 rapidly outcompetes and reduces *S. aureus* viability within 24 hours<sup>7,8</sup>.  
79 Consequently, use of these species within *in vitro* co-culture biofilm models is often  
80 restricted to short incubation periods, such as 24 or 48 hours<sup>7-10</sup>, which is not  
81 representative of long-term biofilm colonisation associated with chronic infection.  
82 Furthermore, use of these short-term *in vitro* models does not address or investigate  
83 factors that could improve the viability of *S. aureus* within a co-culture population.

84

85 There is an urgent need to investigate the impact of interspecies interactions within  
86 biofilms on bacterial persistence, virulence and evolvability in order to develop novel  
87 treatment strategies and circumvent the emergence of adaptive mechanisms, such

88 as those associated with AMR. In this study we aimed to develop and characterise  
89 an *in vitro* dual-species biofilm formed by *S. aureus* and *P. aeruginosa* that is more  
90 representative of chronic infection. A 240-hour co-culture model was established and  
91 used to determine the impact on the antimicrobial susceptibility and individual  
92 mutation rates of both bacterial species. To our knowledge, this is the first  
93 documented approach using a fluctuation assay to assess short-term biofilm  
94 evolvability.  
95

## 96 **Materials and Methods**

### 97 **Bacterial Strains and Growth Conditions**

98 The species/strains utilised in this study were *P. aeruginosa* PAO1, the cystic fibrosis  
99 isolate *P. aeruginosa* PA21, *S. aureus* UAMS-1 and *S. aureus* USA 300 LAC  
100 AH1279 (supplementary Table 1 for more information). Overnight planktonic cultures  
101 of *P. aeruginosa* and *S. aureus* were grown in Luria-Bertani broth, (LB, ForMedium,  
102 UK) and Tryptic Soy Broth, (TSB, Oxoid, UK), respectively. Biofilm cultures were  
103 grown in either Nunc Coated 6 well polystyrene plates (Thermo-Scientific, UK) for  
104 biomass experiments or poly-L-lysine coated glass bottomed dishes (MatTek, USA),  
105 for imaging experiments. Cultures were grown aerobically at 37 °C, with agitation at  
106 120 rpm for planktonic cultures and 50 rpm for biofilms.

107

108 For enumeration and differentiation between *P. aeruginosa* and *S. aureus*,  
109 planktonic and biofilm cultures were plated onto either ceftrimide agar (Oxoid, UK)  
110 supplemented with 1% glycerol (Sigma-Aldrich, UK) and Baird Parker agar (BPA),  
111 supplemented with 5% egg yolk tellurite emulsion (Oxoid, UK).

112

### 113 **Growth Kinetics**

114 Overnight cultures were diluted to  $10^6$  CFU ml<sup>-1</sup> in LB or TSB as appropriate and  
115 incubated for 24 hours at 37 °C with OD<sub>560</sub> measurements taken every 15 minutes  
116 for 15 hours using a 96 well plate reader (BMG Omega).

### 117 **Crystal Violet Assay**

118 *P. aeruginosa* and *S. aureus* biofilms were grown for 72 hours using LB or TSB as  
119 appropriate, with fresh media exchanges every 24 hours. At 24, 48 and 72-hour time  
120 points spent media was removed and biofilms stained with 0.1% (v/v in dH<sub>2</sub>O) crystal  
121 violet for 10 minutes at room temperature. Biofilms were rinsed 3 times with dH<sub>2</sub>O  
122 then 30% acetic acid added to resolubilise the crystal violet. After 10-minute  
123 incubation at room temperature, with light shaking, the OD<sub>550</sub> of the crystal violet  
124 suspension was measured using a spectrophotometer (Jenway 6300), with 30%  
125 acetic acid used as a blank.

126

## 127 Planktonic Competition Assays

128 The relative fitness of both *S. aureus* strains was determined against both  
129 *P. aeruginosa* strains in 20 % BHI (Oxoid, UK) or 20 % BHI supplemented with  
130 hemin (Sigma-Aldrich, UK) at a final concentration of 2, 20 or 100  $\mu\text{M}$ . Overnight  
131 cultures were diluted to  $10^6$  CFU  $\text{ml}^{-1}$  in the appropriate medium to enable co-culture  
132 of the *P. aeruginosa* and *S. aureus* strains at a 1:1 ratio. Cultures were incubated at  
133 37 °C, 120 rpm for 24 hours. Initial and endpoint cell number were obtained by  
134 serially diluting in Hanks Balanced Salt Solution (HBSS, Sigma-Aldrich UK) prior to  
135 plating on ceftrimide agar and BPA. Plates were incubated at 37 °C for 24 hours.

136

137 The relative fitness of each bacterial species and strain was obtained by comparing  
138 the ratio of their Malthusian parameters ( $M_{P.aeruginosa}$  and  $M_{S.aureus}$ ) whereby;

139 
$$M_{P.aeruginosa} = \frac{N_i}{N_f}$$

140

141 
$$M_{S.aureus} = \frac{N_i}{N_f}$$

142

143 
$$W = \frac{\log M_{P.aeruginosa}}{\log M_{S.aureus}}$$

144  $N_i$  = Initial cell number

145  $N_f$  = Final cell number

146  $W$  = Relative fitness

147

## 148 Biofilm Co-Culture Optimisation

149 The ability for *P. aeruginosa* and *S. aureus* to form dual species biofilms was  
150 assessed over 240 hours by adapting a previous method<sup>11</sup>. Overnight cultures of *P.*  
151 *aeruginosa* and *S. aureus* were diluted to  $10^5$  CFU  $\text{ml}^{-1}$  in  $\frac{1}{2}$  strength BHI at a 1:1  
152 ratio of each species. 1 ml was used to inoculate each well of a Nunclon coated 6  
153 well plate (Thermo Scientific, UK) and incubated for 6 hours at 37 °C, 50 rpm to  
154 facilitate bacterial attachment. Media was then replaced with 4 ml of 20% BHI or  
155 20% BHI supplemented with hemin (Sigma-Aldrich, UK) at a final concentration of 2,  
156 20 or 100  $\mu\text{M}$ . Media was replaced after a further 18 hours, then every 24 hours

157 thereafter. After 24, 72, 168 and 240 hours, biofilms were rinsed twice with HBSS to  
158 remove non-adherent cells and harvested using a cell scraper. Cell suspensions  
159 were serially diluted in HBSS and plated onto cefrimide agar and BPA for selective  
160 enumeration of *P. aeruginosa* and *S. aureus*, respectively.  
161

## 162 Confocal Laser Scanning Microscopy of *P. aeruginosa* and *S. aureus* biofilms

163 Mono- and co-culture biofilms of *P. aeruginosa* PA21 with *S. aureus* UAMS-1 or *S.*  
164 *aureus* LAC were cultured to assess biofilm architecture. Biofilms were grown using  
165 20% BHI supplemented with 20  $\mu\text{M}$  hemin in MatTek dishes. Biofilms were assessed  
166 at 24, 72, 168 and 240 hours of growth. Prior to imaging, spent media was removed  
167 and the biofilms rinsed twice with HBSS before staining for 15 minutes with 1 ml of  
168 LIVE BacLight Bacterial Gram stain (Life Technologies), (3  $\mu\text{l ml}^{-1}$  SYTO9, 2  $\mu\text{l ml}^{-1}$   
169 hexidium iodide). Imaging was performed using an inverted Leica TCS SP8 confocal  
170 laser scanning microscope and a 63x glycerol immersion lens, with 1  $\mu\text{m}$  vertical  
171 sections. Fluorescent dyes were excited using concurrent 514 nm and 561 nm  
172 lasers.  
173

## 174 Antimicrobial Susceptibility Testing

175 The minimum inhibitory concentration (MIC) of rifampicin (Sigma-Aldrich, UK) was  
176 determined for *P. aeruginosa* PA21 and *S. aureus* UAMS-1 using the broth  
177 microdilution method<sup>12</sup>, with a two-fold dilution series of rifampicin (0 to 128  $\mu\text{g ml}^{-1}$ ).  
178 Following a 24-hour incubation at 37 °C, the endpoint OD<sub>680</sub> was measured with a  
179 microplate reader (BMG Omega). The MIC was the antimicrobial concentration that  
180 resulted in no bacterial growth.  
181

182 The biofilm minimum bactericidal concentrations (MBC) of tobramycin, vancomycin  
183 and HT61<sup>12</sup>, was determined for mono- and co-culture biofilms of *P. aeruginosa*  
184 PA21 and *S. aureus* UAMS-1 using a method adapted from Howlin *et al* (2015)<sup>13</sup>.  
185 Biofilms were cultured for 72 hours in Nunclon coated 6 well plates as previously  
186 described using 20% BHI supplemented with 20  $\mu\text{M}$  hemin. Spent media was  
187 replaced with antimicrobial supplemented media (two-fold dilution series between 0  
188 and 128  $\mu\text{g ml}^{-1}$ ). After an additional 24 hours of incubation, biofilms were rinsed

189 twice with HBSS, harvested with a cell scraper and serially diluted and plated onto  
190 cetrимide agar and BPA. The biofilm MBCs were identified as the concentration  
191 leading to a 3-log reduction in CFU's.

192

### 193 Estimation of Planktonic and Biofilm Mutation Rates

194 Fluctuation tests were performed for planktonic cultures as previously described in  
195 Foster (2006)<sup>14</sup> and adapted for use with biofilm cultures grown in 6 well plates.

196 Overnight cultures of *P. aeruginosa* PA21 and *S. aureus* UAMS-1 were diluted to 10<sup>3</sup>  
197 CFU ml<sup>-1</sup> in 50% BHI, either in isolation, or in a 1:1 co-culture. 30 parallel planktonic  
198 or biofilm cultures were initiated using 1 ml of the inoculum in 20 ml universal  
199 containers or Nunclon coated 6 well plates, respectively. All cultures were incubated  
200 at 37 °C, 50 rpm for 6 hours, with planktonic cultures tilted at approximately 45° to  
201 allow for media movement.

202

203 Planktonic cultures were centrifuged at 4000 x g for 15 minutes and the cell pellet re-  
204 suspended in 4 ml of 20% BHI supplemented with 20 µM hemin. For biofilm cultures,  
205 spent media was replaced with 4 ml of 20% BHI supplemented with 20 µM hemin.  
206 Cultures were incubated at 37 °C, 50 rpm for a further 18 hours. Following  
207 incubation, planktonic cultures were centrifuged at 4000 x g, the cell pellet rinsed  
208 twice with HBSS, then re-suspended in 500 µl HBSS. Biofilm cultures were rinsed  
209 twice with HBSS, harvested using a cell scraper and resuspended into 500 µl HBSS.

210

211 Final cell counts were determined by plating 5 random cultures onto cetrимide agar  
212 and BPA. Half of each remaining planktonic and biofilm suspension was then plated  
213 onto cetrимide agar and BPA supplemented with 64 µg ml<sup>-1</sup> or 0.25 µg ml<sup>-1</sup> rifampicin  
214 (4 X calculated MIC for each species) for selection of spontaneous *P. aeruginosa* or  
215 *S. aureus* mutants, respectively. Plates were incubated at 37 °C and enumerated  
216 after 24 hours (plates without antibiotics) or 48 hours (rifampicin plates).

217

218 Mutation rates were calculated using FALCOR and the Ma-Sandri-Sarkar Maximum  
219 Likelihood Estimator<sup>15</sup>. Fluctuation tests were performed in biological duplicate (60  
220 technical replicates).

221



## 222 Genomic Comparison of *P. aeruginosa* PAO1 and PA21

223 Short read sequencing of both *P. aeruginosa* strains was performed by MicrobesNG  
224 on Illumina platforms using 250 bp paired end reads. Long read sequencing was  
225 performed using the Minlon sequencing platform (Oxford Nanopore, UK and the  
226 rapid barcoding kit as per manufacturer's instructions. Long read data was  
227 basecalled using albacore and trimmed and demultiplexed using PoreChop  
228 (<https://github.com/rrwick/Porechop>) with default settings.

229

230 Hybrid assemblies were performed *de novo* using Unicycler<sup>16</sup> in normal mode  
231 resulting and annotated using PROKKA<sup>17</sup>. Annotations were preserved and  
232 genomes compared using RAST<sup>18,19</sup>.

233

## 234 Statistical Analysis

235 Statistical analyses were performed using GraphPad Prism version 7.0d for Mac.  
236 Crystal violet data and comparisons between single species biofilms were made  
237 using multiple t-tests with the Holm-Sidak correction. Effects of media composition  
238 and bacterial competition on fitness were analysed using a 2-way ANOVA. Kruskal-  
239 Wallis tests with Dunn's multiple comparisons were used to analyse within time point  
240 comparisons of biofilm co-culture and for comparison of biofilm maximum thickness,  
241 derived from microscopy data. For all of the above statistical tests,  $\alpha \leq 0.05$ .

242

243 The R package, RSalvador<sup>20</sup>, was used to calculate 94% confidence intervals for the  
244 fluctuation test data. Confocal image z-stacks were analysed using the COMSTAT 2  
245 plug in for ImageJ (downloadable at [www.comstat.dk](http://www.comstat.dk))<sup>21</sup>.

246

247 Statistical significance was determined between fluctuation tests by manually  
248 comparing 94 % confidence intervals (shown to mimic statistical tests for  $p \leq 0.01$   
249 and a valid statistical approach when comparing fluctuation test data with differing  
250 terminal cell population sizes<sup>22,23</sup>.

251

252

## 253 Results

254 Planktonic co-culture of *P. aeruginosa* and *S. aureus* did not affect relative  
255 fitness of either species, despite differences in growth kinetics or biofilm  
256 formation.

257 Basic phenotyping of each strain of *P. aeruginosa* and *S. aureus* was performed,  
258 comparing growth kinetics, (Figure 1A), capacity to form biofilms (Figure 1B), and the  
259 relative fitness of each strain when grown as planktonic co-cultures in a selection of  
260 defined media (Figure S1). No difference in growth kinetics was observed for either  
261 strain of *S. aureus*, and both exhibited similar biofilm-forming capacities with no  
262 statistically significant differences at any time point (multiple t-tests, Holm-Sidak  
263 correction; 24 hr  $p = 0.505$ , 48 hr  $p = 0.615$ , 72 hr  $p = 0.893$ ).

264


265 For *P. aeruginosa*, the exponential phase of growth for PAO1 was approximately 2  
266 hours longer than that of PA21, although final cell density was equal between  
267 cultures (data not shown). PAO1 formed biofilms with considerably more biomass at  
268 each measured time point compared to PA21, (multiple t-tests, Holm-Sidak  
269 correction; 24 hr  $p = 0.0001$ , 48 hr  $p < 0.0001$ , 72 hr  $p = 0.0002$ ). Both strains formed  
270 more biofilm biomass than either strain of *S. aureus*.

271

272 Iron availability is known to be important for the growth of pathogens within the cystic  
273 fibrosis lung<sup>24,25</sup> and hemin was chosen to mimic a potential *in vivo* source of ferric  
274 iron donor. Planktonic relative fitness was determined in 20% BHI supplemented with  
275 hemin to a final concentration of either 2, 20 or 100  $\mu\text{M}$ . Relative fitness was equal to  
276 1 for each combination in all media compositions with no statistical differences  
277 between any calculated values, suggesting no decrease in fitness for either species  
278 during planktonic co-culture (2-way ANOVA, interaction  $p = 0.0538$ , bacterial  
279 combinations  $p = 0.1960$ , media choice  $p = 0.5100$ )

280

281



282

283 *Figure 1: Growth Kinetics and Biofilm-forming Ability of P. aeruginosa PAO1, PA21 and S. aureus UAMS-1 and*

284 *LAC. A) S. aureus UAMS-1 and LAC exhibit near identical growth kinetics and biofilm formation. P. aeruginosa*

285 *PAO1 and PA21 both enter exponential phase at the same point in time, but PA21 enters stationary earlier*

286 *resulting in reduced culture density. B) Biofilm formation of PA21 is less than that measured for PAO1 at all time*

287 *points. Growth curves: n = 12 for S. aureus, n = 3 for P. aeruginosa, Crystal violet assays: n = 3. Error bars*

288 *represent standard error of the mean. \*\*\*\* p > 0.0001, \*\*\* p > 0.001. P values calculated using multiple unpaired*

289 *student t-tests, corrected using the Holm-Sidak method.*

290

291

292

293

294 **Addition of Hemin Does Not Affect Viability of *S. aureus* and *P. aeruginosa***  
295 **During Growth as a Single Species Biofilm**

296 Single species biofilms of each *P. aeruginosa* strain were unaffected by  
297 supplementation of media with hemin, although there was intra-strain variation (see  
298 supplementary information, figure S2). *P. aeruginosa* PA21 formed biofilms with a  
299 lower cell density compared to those formed by *P. aeruginosa* PAO1 at 24 hours in  
300 all media tested (multiple unpaired t-tests at for each media combination,  $p < 0.05$ ).  
301 However, by 240 hours of growth any difference in cell density was statistically  
302 insignificant ( $p > 0.05$ )

303

304 Both *S. aureus* UAMS-1 and *S. aureus* LAC formed biofilms with equal cell densities  
305 at 24 and 72 hours, regardless of the hemin concentration in the media. However, by  
306 168 hours, regardless of hemin supplementation, *S. aureus* LAC biofilms were  
307 approximately 1 log lower cell density compared to *S. aureus* UAMS-1, a decrease  
308 that was still apparent following 240 hours of growth ( $p < 0.05$ ).

309

310

311

312 *P. aeruginosa* strain selection and increased hemin concentrations can  
313 improve *S. aureus* survival during Biofilm Co-Culture.

314 Co-culture biofilms of *P. aeruginosa* PAO1 or PA21 with *S. aureus* UAMS-1 or LAC  
315 were grown for 10 days (240 hours) and the impact of different hemin concentrations  
316 on the viability of the co-cultures assessed (Figure 2). *P. aeruginosa* viability was not  
317 affected by the addition of hemin to the media. While hemin improved *S. aureus*  
318 viability, it was present at lower abundance than *P. aeruginosa* in all co-cultures.

319

320 When *S. aureus* UAMS-1 was co-cultured with *P. aeruginosa* PAO1, no viable *S.*  
321 *aureus* cells were identified after 168 hours of growth, regardless of hemin  
322 supplementation. Hemin supplementation slightly reduced UAMS-1 viability at 24  
323 hours, although this decrease was not statistically significant with 20  $\mu\text{M}$  hemin  
324 (Figure 2, panel A, 24 hour  $p$  values; No hemin vs 2  $\mu\text{M}$  = 0.0167, No hemin vs 20  
325  $\mu\text{M}$  > 0.999, No hemin vs 100  $\mu\text{M}$  = 0.0006).

326

327 *S. aureus* LAC was not detectable following 72 hours of growth with *P. aeruginosa*  
328 PAO1. Hemin supplementation improved *S. aureus* viability so that it was detectable  
329 at 72 hours, although due to a number of zero counts in 2  $\mu\text{M}$  hemin, the improved  
330 viability was only significant in 20 or 100  $\mu\text{M}$  hemin (72 hour  $p$  values No hemin vs 2  
331  $\mu\text{M}$  = 0.7089, No hemin vs 20  $\mu\text{M}$  = 0.0015, No hemin vs 100  $\mu\text{M}$  = 0.0241).

332 However, similar to *S. aureus* UAMS-1, *S. aureus* LAC was not detectable after 168  
333 hours regardless of hemin supplementation.

334

335 Conversely, both strains of *S. aureus* were detectable after 240 hours of co-culture  
336 with *P. aeruginosa* PA21 (Figure 2, panels B and D). Hemin supplementation  
337 improved viability further, although for both strains, *S. aureus* counts in 2  $\mu\text{M}$  hemin  
338 were statistically identical to counts in non-supplemented media at all time points ( $p$   
339 > 0.9999). In the non-supplemented and 2  $\mu\text{M}$  hemin supplemented media *S. aureus*  
340 UAMS-1 viability decreased over 240 hours from approx.  $10^5$  CFU  $\text{cm}^{-2}$  to  $10^2$  CFU  
341  $\text{cm}^{-2}$ , whereas *S. aureus* LAC remained at a density between approximately  $10^2$  and  
342  $10^3$  CFU  $\text{cm}^{-2}$ . Supplementation of media with 20 and 100  $\mu\text{M}$  hemin increased *S.*  
343 *aureus* viability compared to non-supplemented media with final counts at 240 hours


344 approximately  $10^5$  CFU  $\text{cm}^{-2}$  for both strains (*S. aureus* No hemin vs 20  $\mu\text{M}$  *p* values;  
345 UAMS-1 240 hour < 0.0001, LAC 240 hour = 0.0033). *S. aureus* viability in media  
346 supplemented with 100  $\mu\text{M}$  hemin was similar to that in media supplemented with 20  
347  $\mu\text{M}$  hemin, with the exception of *S. aureus* UAMS-1 at 24 hours, which was 1 log  
348 lower in density ( $p < 0.0001$ ). All other differences were statistically insignificant (20  
349  $\mu\text{M}$  vs 100  $\mu\text{M}$  *S. aureus* UAMS-1 *p* values; 72 hour > 0.9999, 168 hour > 0.9999,  
350 240 hour = 0.5851 and 20  $\mu\text{M}$  vs 100  $\mu\text{M}$  *S. aureus* LAC *p* values; 24 hour = 0.0753,  
351 72 hour > 0.9999, 168 hour = 0.4190, 240 hour > 0.9999)

352


353 Addition of 100  $\mu\text{M}$  hemin did not discernibly improve viability of *S. aureus* or *P.*  
354 *aeruginosa* compared to supplementation with 20  $\mu\text{M}$  hemin. For this reason,  
355 subsequent assays utilised hemin at a concentration of 20  $\mu\text{M}$  in 20 % BHI.

356


**A) *P. aeruginosa* PAO1 and *S. aureus* UAMS-1**




**B) *P. aeruginosa* PA21 and *S. aureus* UAMS-1**



**C) *P. aeruginosa* PAO1 and *S. aureus* LAC**



**D) *P. aeruginosa* PA21 and *S. aureus* LAC**



■ *S. aureus* UAMS-1    
 ■ *S. aureus* LAC    
 ■ *P. aeruginosa* PAO1    
 ■ *P. aeruginosa* PA21

357

358

359

360

361

362

363

364

365

366

367

368

Figure 2: Effects of hemin supplementation on the dynamics of *P. aeruginosa* and *S. aureus* biofilm co-culture.

The ability of *S. aureus* to survive in co-culture depends on a combination of the *P. aeruginosa* strain and the

hemin concentration of the media. Both strains of *S. aureus* were less successful in co-culture with *P. aeruginosa*

PAO1, compared to *P. aeruginosa* PA21. Addition of hemin at 2  $\mu$ M facilitated the growth of *S. aureus* LAC with

*P. aeruginosa* PAO1 for at least 72 hours and addition of hemin at either 20  $\mu$ M or 100  $\mu$ M significantly improved

the viability of both *S. aureus* UAMS-1 and *S. aureus* LAC when in co-culture with *P. aeruginosa* PA21. Kruskal

Wallis with Dunn's multiple comparison performed to determine significance between different media

compositions. Points of note are mentioned in the text. Due to the large number of comparisons, significance

levels are not presented on chart and are instead compiled in the supplementary information. n = 9 from 3

biological replicates

## 369 Visualisation of *P. aeruginosa* and *S. aureus* Biofilm Co-Cultures

370 Representative images are presented in Figure 3 (*P. aeruginosa* PA21 and *S.*  
371 *aureus* UAMS-1) and Figure 4, (*P. aeruginosa* PA21 and *S. aureus* LAC).

372


373 When cultured in isolation, *P. aeruginosa* PA21 forms microcolony structures after  
374 24 hours of growth. These structures expand after 72 hours and by 168 hours of  
375 growth have formed a confluent layer. By 240 hours the overall density of the biofilm  
376 appears to have reduced, although the remaining microcolonies do contribute to  
377 increased biofilm thickness (see supplementary information, Figure S3). Both *S.*  
378 *aureus* UAMS-1 and *S. aureus* LAC undergo similar biofilm development,  
379 corroborating the previously obtained crystal violet and CFU data (Figure 1 and  
380 Figure S2, respectively), forming a uniform sheet of biomass without any significant  
381 changes in maximum biofilm thickness over 240 hours (Figure S3,  $p > 0.05$ ).

382

383 During co-culture of *P. aeruginosa* PA21 and *S. aureus* UAMS-1, *S. aureus* is  
384 distributed uniformly throughout the biofilm for the first 72 hours. By 168 hours of  
385 growth, *S. aureus* appears to have clustered around cellular aggregates, (indicated  
386 by the yellow colour within the image resulting from a high number of green and red  
387 cells in close proximity, similar to the observation made by DeLeon *et al*<sup>10</sup>. By 240  
388 hours, the dense areas of *Staphylococcal* cells appear to have lessened, although it  
389 still found throughout the biofilm. Co-culture of *S. aureus* LAC with *P. aeruginosa*  
390 PA21 shows a similar morphology over the first 72 hours of growth. Unlike *S. aureus*




391 UAMS-1, *S. aureus* LAC remains uniformly distributed at 168 and 240 hours with far  
392 fewer localised aggregates.  
393



394  
395 *Figure 3: Representative Confocal Laser Scanning Microscopy images of a single and dual species biofilms of P.*  
396 *aeruginosa* PA21 and *S. aureus* UAMS-1 over 240 hours. Biofilms were stained with a fluorescent Gram stain for  
397 differentiation between species. Hexidium iodide stains Gram positive bacteria to fluoresce red, (*S. aureus*), while  
398 SYTO9 counterstains the remaining Gram negative bacteria (*P. aeruginosa*) and fluoresces green. Scale bars  
399 represent 25  $\mu\text{m}$ .

400

401



402

403 *Figure 4: Representative Confocal Laser Scanning Microscopy images of a single and dual species biofilms of P.*  
404 *aeruginosa PA21 and S. aureus LAC over 240 hours. Biofilms were stained with a fluorescent Gram stain for*  
405 *differentiation between species. Hexidium iodide stains Gram positive bacteria to fluoresce red, (S. aureus), while*  
406 *SYTO9 counterstains the remaining Gram-negative bacteria (P. aeruginosa). Scale bars represent 25 μm.*

407

408

409

410

411

412

413

414

415

416

417

418

419 **Biofilm Co-Culture Alters the Antimicrobial Susceptibility of *P. aeruginosa* and**  
420 ***S. aureus***

421 *Table 1: Antimicrobial susceptibility of *P. aeruginosa* PA21 and *S. aureus* UAMS-1 in single and dual species*  
422 *biofilms. Biofilm minimum bactericidal concentrations (MBCs) of tobramycin and vancomycin defined as the*  
423 *concentration of antimicrobial that reduced the viable counts of each species by 3 log or more. Values in table*  
424 *represent antimicrobial concentration in  $\mu\text{g ml}^{-1}$ . Biofilm co-culture increased the tobramycin MBC for *P.**  
425 **aeruginosa* from 2  $\mu\text{g ml}^{-1}$  to 4  $\mu\text{g ml}^{-1}$  and decreased the Biofilm MBC of *S. aureus* from 16  $\mu\text{g ml}^{-1}$  to 2  $\mu\text{g ml}^{-1}$ .*  
426 *HT61 was not effective against *P. aeruginosa*, however biofilm co-culture increased *S. aureus* susceptibility four-*  
427 *fold (Single species MBC = 64  $\mu\text{g ml}^{-1}$  Co-culture MBC = 16  $\mu\text{g ml}^{-1}$ ) Co-culture did not alter susceptibility of*  
428 *either species to vancomycin. n = 9, from 3 biological replicates.*

	<b><i>P. aeruginosa</i> PA21</b>		<b><i>S. aureus</i> UAMS-1</b>	
<b>Antimicrobial</b>	Single Species	Dual Species	Single Species	Dual Species
Tobramycin	2	4	16	2
Vancomycin	> 128	> 128	> 128	> 128
HT61	> 128	> 128	64	16

429

430 To demonstrate that the biofilm model could be utilised in phenotyping experiments  
431 the antimicrobial susceptibility of established mono- and co-culture biofilms of *S.*  
432 *aureus* UAMS-1 and *P. aeruginosa* PA21 was determined using two antimicrobials in  
433 clinical use (tobramycin and vancomycin) and a novel antimicrobial compound  
434 currently in development (HT61).

435

436 Whereas vancomycin and HT61 had no effect on *P. aeruginosa* viability when grown  
437 as either a single or dual-species biofilm, the MBC of tobramycin increased from 2 to  
438 4  $\mu\text{g ml}^{-1}$ . Similarly, *S. aureus* viability was not affected by vancomycin in either  
439 single or dual-species biofilms, however, the tobramycin and HT61 MBCs were  
440 reduced eightfold (16 to 2  $\mu\text{g ml}^{-1}$ ) and fourfold (64 to 16  $\mu\text{g ml}^{-1}$ ) respectively.


441

442 **Biofilm co-culture of *P. aeruginosa* and *S. aureus* significantly increases the**  
443 **mutation rate of each species**

444 Understanding whether interspecies interactions can alter bacterial evolvability is  
445 incredibly relevant, considering the rapid emergence of AMR. The Luria-Delbrück  
446 fluctuation test was applied to both single species and dual species co-cultures of *P.*  
447 *aeruginosa* PA21 and *S. aureus* UAMS-1, both in planktonic and biofilm culture to  
448 measure the spontaneous mutation rate (via the development of rifampicin  
449 resistance) of each species (Figure 5).

450

451 In planktonic mono-culture, the mutation rates of *P. aeruginosa* PA21 and *S. aureus*  
452 UAMS-1 were low, at  $2.84 \times 10^{-9}$  and  $1.37 \times 10^{-9}$  mutations per cell division,  
453 respectively. Planktonic co-culture led to an increase in mutation rate for both  
454 species to  $8.90 \times 10^{-9}$  mutations per cell division. Biofilm mono-culture resulted in a  
455 similar increase to  $1.03 \times 10^{-8}$  and  $1.32 \times 10^{-8}$  mutations per cell division for *P.*  
456 *aeruginosa* PA21 and *S. aureus* UAMS-1, respectively. Following biofilm co-culture,  
457 the mutation rate of *P. aeruginosa* remained at a similar level ( $1.05 \times 10^{-8}$  mutations  
458 per cell division). However, the mutation rate of *S. aureus* increased to  $7.44 \times 10^{-7}$   
459 mutations per cell division, which is an approximately 500-fold relative increase  
460 compared to the rate during planktonic mono-culture.



461

Species	Culture Type		CFUs Plated (Nt)	Mutation Rate
<i>P. aeruginosa</i>	Planktonic	Mono-culture	$9.83 \times 10^9$	$2.84 \times 10^{-9}$
		Co-culture	$3.40 \times 10^9$	$8.90 \times 10^{-9}$
	Biofilm	Mono-culture	$3.21 \times 10^8$	$1.03 \times 10^{-8}$
		Co-culture	$2.73 \times 10^8$	$1.05 \times 10^{-8}$
<i>S. aureus</i>	Planktonic	Mono-culture	$3.44 \times 10^9$	$1.37 \times 10^{-9}$
		Co-culture	$2.58 \times 10^8$	$8.90 \times 10^{-9}$
	Biofilm	Mono-culture	$5.60 \times 10^8$	$1.32 \times 10^{-8}$
		Co-culture	$2.62 \times 10^6$	$7.44 \times 10^{-7}$

462

463

Figure 5: Effect of Biofilm Growth on Mutation Rate of *P. aeruginosa* PA21 and *S. aureus* UAMS-1.

464

Following biofilm mono-culture, both species are shown to have an increased rate of mutation, (*P. aeruginosa*

465

$1.03 \times 10^{-8}$ , *S. aureus*  $1.32 \times 10^{-8}$ ). The rate of mutation for *P. aeruginosa* stays at this level following co-culture

466

planktonic growth and co-culture biofilm growth suggesting that while species interactions are important, in this

467

case, the species interactions between *P. aeruginosa* and *S. aureus* do not impact the evolvability of *P.*

468

*aeruginosa* more than the conditions of biofilm growth. The mutation rate of *S. aureus* following planktonic

469

co-culture is approximately the same as that following biofilm mono-culture (Planktonic co-culture:  $8.90 \times 10^{-9}$ ,

470

Biofilm mono-culture:  $1.32 \times 10^{-8}$ ), suggesting that the pressures associated with the presence of planktonic *P.*

471

*aeruginosa* on staphylococcal evolvability is similar to those associated with mono-culture biofilm growth.

472

However, following biofilm co-culture, the mutation rate of *S. aureus* is highly elevated to  $7.44 \times 10^{-7}$ . This

473

suggests that both biofilm growth and the interspecies interactions present following biofilm co-culture with *P.*

474

*aeruginosa* may be important to understanding the evolvability of *S. aureus*. Error bars represent 94% confidence

475

intervals. \*\* represents  $p \leq 0.01$ , obtained by comparing overlap of confidence intervals. This method is a valid

476

comparison as calculation of confidence intervals and accounts for differences in the terminal population

477

density<sup>23</sup>

## 478 *P. aeruginosa* Genome Comparison Reveals Strain Specific Features

479 Due to the differing abilities of *P. aeruginosa* PAO1 and *P. aeruginosa* PA21 to form  
480 co-culture biofilms, the genomes of these two strains were sequenced and compared  
481 to identify whether any obvious genetic differences might explain the different co-  
482 culture phenotypes. Assembly statistics and a complete list of differential genomic  
483 features are presented in the supplementary information.

### 484 **Genes Absent in *P. aeruginosa* PA21**

485 77 genes were identified that were present only in *P. aeruginosa* PAO1. Of these, 41  
486 were hypothetical, resulting in 36 annotated genes (complete list in S1), which  
487 include numerous phage proteins, helicases, manganese catalase and a number of  
488 genes associated with lipopolysaccharide production such as the virulence  
489 associated Wzx and Wzy flippases.

490

### 491 **Additional Genes in *P. aeruginosa* PA21**

492 500 genes were found exclusively in *P. aeruginosa* PA21. Of these, 234 coded for  
493 hypothetical proteins while 266 genes were annotated across multiple categories  
494 including virulence factors, resistance genes, cell signalling, metabolism, as well as  
495 extensive phage associated proteins and proteins associated with DNA  
496 recombination (complete list in S2). While there are no specific genes that appear to  
497 be directly associated with the improved ability of *P. aeruginosa* PA21 to form a  
498 stable co-culture biofilm with *S. aureus*, there are numerous proteins of interest such  
499 the phd-doc toxin antitoxin (TA) system as well as additional proteins associated with  
500 iron uptake, such as periplasmic TonB, important for siderophore transport and  
501 uptake<sup>26</sup>.

502

503

## 504 Discussion and Conclusion

505 In this paper, we developed a long-term *in vitro* biofilm co-culture of *P. aeruginosa*  
506 and *S. aureus* that could be maintained for at least 10 days and is more  
507 representative of chronic infection compared to current 24-48 hour models. Following  
508 optimisation of the biofilm co-culture we determined how biofilm co-culture altered  
509 the evolvability of each bacterial species, and using a genomic based approach  
510 compared and identified features of *P. aeruginosa* that could be implicated in  
511 sustaining a biofilm co-culture with *S. aureus*.

512

513 When comparing planktonic and biofilm co-culture, we found that the viability of *S.*  
514 *aureus* was only negatively affected during biofilm growth. This was interesting as  
515 numerous studies have shown that the viability of *S. aureus* is negatively affected by  
516 *P. aeruginosa* even in planktonic culture<sup>10,27-29</sup>. However, Miller *et al* (2017) found  
517 that use of a more nutrient rich medium improved *S. aureus* survival<sup>30</sup>. This  
518 suggests, consistent with our results that media composition is an important  
519 consideration for the development of a co-culture model.

520

521 We found that both *P. aeruginosa* strain and exogenous hemin concentration  
522 impacted *S. aureus* survival during biofilm co-culture. Altered levels of *S. aureus*  
523 killing by *P. aeruginosa* has been linked to latter's ability to form biofilms; those that  
524 form less biofilm are less prone to *S. aureus* killing<sup>7</sup>. Based on crystal violet staining,  
525 *P. aeruginosa* PAO1 formed more robust single species biofilms than *P. aeruginosa*  
526 PA21 and also reduced the number of viable *S. aureus* during biofilm co-culture. It  
527 has been demonstrated that *P. aeruginosa* isolates taken from patients co-infected  
528 with *P. aeruginosa* and *S. aureus* are less competitive towards *S. aureus*<sup>8,27</sup>. While  
529 the exact clinical background of *P. aeruginosa* PA21 in relation to *S. aureus* co-  
530 culture is not available, this could be a factor that favours its co-culture with *S.*  
531 *aureus*.

532

533 We showed that increasing the concentration of hemin improved *S. aureus* viability  
534 during co-culture with *P. aeruginosa* PA21. During biofilm co-culture, *S. aureus* is  
535 lysed and used as an iron source for *P. aeruginosa* in a *Pseudomonas* quinolone  
536 signal, PQS, mediated process that is decreased in iron rich environments<sup>7,31</sup>. By

537 increasing the exogenous iron concentration, it is possible that *P. aeruginosa* PA21  
538 PQS expression was reduced, reducing *S. aureus* lysis. Measuring the changes in  
539 expression of associated genes in *P. aeruginosa* PA21 such as *pqsA* and *pqsH*, with  
540 differing concentrations of hemin may provide insight into this scenario.

541

542 Sequencing of the two *P. aeruginosa* genomes identified features that could be  
543 important targets for further investigation. The presence of additional iron uptake  
544 components and lack of manganese catalase enzymes, (typical for bacteria  
545 occupying low iron environments/possess ineffective iron uptake mechanisms)<sup>32</sup>,  
546 may mean that PA21 at the uptake of exogenous iron than PAO1. If uptake is more  
547 efficient, that could negatively regulate the production of molecules that are  
548 produced to lyse *S. aureus* and utilise it as an iron source instead<sup>7</sup>. As an aside, it  
549 was found that *P. aeruginosa* PA21 still contained genes encoding the siderophores  
550 pyoverdine and pyochelin, *pvdA* and *pchE*, respectively. The presence of these  
551 genes has previously been associated with increased killing of *S. aureus* in co-  
552 culture<sup>9</sup>. As *P. aeruginosa* PA21 was less lethal to *S. aureus* than *P. aeruginosa*  
553 PAO1, it suggests these genes are not implicated and the improved survival is a  
554 result of a different mechanism. Expression of the phd-doc TA system has been  
555 linked with translation inhibition<sup>33</sup>. If this module is activated by PA21 during co-  
556 culture, it could facilitate *S. aureus* survival by slowing *P. aeruginosa* growth and/or  
557 increase *S. aureus* tolerance. Further investigation into these elements would be  
558 required.

559

560 Mutation frequency is known to be elevated in biofilms<sup>34,35</sup>, which is a measure of the  
561 abundance of mutants within a population. However, mutation frequency can be  
562 distorted by the expansion of lineages harbouring low probability, “jackpot mutations”  
563 that occur during the early stages of growth. On the other hand, mutation rate, which  
564 measures the number of mutations sustained by a cell during its lifetime, accounts  
565 for jackpot mutations and is overall, a more robust measurement<sup>14</sup>. By applying the  
566 fluctuation test to planktonic and biofilm mono- and co-cultures, we provide  
567 additional evidence of this. We show that interspecies interactions can modulate  
568 rates further and highlight the importance of understanding interspecies interactions  
569 within bacterial communities. It has been demonstrated that planktonic cultures of *P.*  
570 *aeruginosa* undergo a different evolutionary trajectory when cultured in the presence



571 of *S. aureus*, obtaining mutations in lipopolysaccharide biosynthesis genes and  
572 increased resistance to  $\beta$ -lactam antimicrobials<sup>36</sup>. As such, understanding the impact  
573 of these complex community interactions could prove critical in limiting AMR.

574

575 Biofilm co-culture of *P. aeruginosa* and *S. aureus* caused the two species to present  
576 with different levels of antimicrobial susceptibility compared to growth as a single  
577 species biofilm. For this study, we chose to test the efficacy of tobramycin, an  
578 aminoglycoside that is effective against both *P. aeruginosa* and *S. aureus*, and  
579 vancomycin, an important glycopeptide utilised in the control of *Staphylococcal*  
580 infections. The novel antimicrobial HT61 which has shown activity against  
581 *Staphylococcus spp.* was also tested<sup>12</sup>.

582

583 Biofilm co-culture caused *P. aeruginosa* to become less susceptible to tobramycin  
584 and *S. aureus* to become more susceptible. These effects have both been previously  
585 documented. Interactions between *P. aeruginosa* derived Psl polysaccharide and *S.*  
586 *aureus* derived Staphylococcal protein A can cause aggregates of *P. aeruginosa* to  
587 form, decreasing overall susceptibility to tobramycin<sup>37</sup>. Conversely, *P. aeruginosa*  
588 rhamnolipids production can potentiate tobramycin uptake in *S. aureus* cells<sup>38</sup>.  
589 *P. aeruginosa* production of the endopeptidase LasA has been linked to increased  
590 vancomycin susceptibility in *S. aureus*<sup>38</sup>, which was not observed in this study.

591

592 *S. aureus* susceptibility to HT61 was also increased during biofilm co-culture. HT61  
593 is more effective against stationary phase cells due to the introduction of anionic  
594 membrane components<sup>12,39</sup>. Mechanisms that decrease *S. aureus* growth rates  
595 could potentiate HT61. Vancomycin tolerance has been associated with a similar  
596 mechanism in *P. aeruginosa* and *S. aureus* co-cultures<sup>40</sup>.

597

598

599

600

601

602

603

## 604 Limitations and Conclusions

605 The *in vitro* model described here is reproducible, accessible to all with basic  
606 laboratory facilities and mimics viability counts of *in vivo* models where *P. aeruginosa*  
607 is dominant and *S. aureus* is 2-3 log lower in abundance<sup>29</sup>. As such, it will be useful  
608 for fundamental studies of *P. aeruginosa* and *S. aureus* interactions. However,  
609 further investigation will reveal whether our findings apply within *ex vivo* host tissue  
610 models of infection, or within *in vivo* studies<sup>41</sup>. Examples of such *ex vivo* models  
611 include a model of primary ciliary dyskinesia, which incorporates *Haemophilus*  
612 *influenzae* in co-culture with diseased ciliated epithelial cells<sup>42</sup>, a model of *P.*  
613 *aeruginosa* utilising pig bronchioles<sup>43</sup> or a dual species wound model of *P.*  
614 *aeruginosa* and *S. aureus* utilising immortalised keratinocytes as a substratum<sup>44</sup>.

615

616 In summary, we have described the creation and optimisation of a stable, co-culture  
617 biofilm model of *P. aeruginosa* and *S. aureus* and demonstrated that co-culture of  
618 these organisms can increase the rate of bacterial mutation, which could have  
619 important implications for studying bacterial evolution, adaptation and AMR within  
620 multispecies consortia.

## 621 Acknowledgements

622 The authors would like to acknowledge the assistance of Steven Pullan of Public  
623 Health England for his assistance and expertise involving the nanopore sequencing  
624 of *P. aeruginosa* PAO1. The authors would also like to thank David Cleary  
625 (University of Southampton) for his valuable discussions surrounding analysis of the  
626 genomic data and whole genome comparisons and Qi Zheng (Texas A&M School of  
627 Public Health) for his advice surrounding the use of the rSalvador package and  
628 analysis of fluctuation analysis data. Short read genome sequencing was provided  
629 by MicrobesNG (<http://www.microbesng.uk>), which is supported by the BBSRC  
630 (grant number BB/L024209/1). In addition, the authors acknowledge the use of the  
631 IRIDIS High Performance Computing Facility, and associated support services at the  
632 University of Southampton, in the completion of this work. YM and AC made  
633 important contributions to the conception and design of the study and critiqued the  
634 output for important intellectual content.

635

636 This work was funded by a Biotechnology and Biological Sciences Research Council  
637 CASE Studentship award in partnership with Helperby Therapeutics,  
638 (BB/L016877/1). ARH was supported by NIH public health service grant AI083211.  
639 OS was supported by a Cystic Fibrosis Trust UK grant (Registered Charity No. for  
640 England and Wales 1079049) as part of a Strategic Research Centre titled  
641 “Pseudomonal infection in CF”.  
642  
643

## 644 **References**

- 645
- 646 1. WHO. Antimicrobial resistance. Global Report on Surveillance. *Bulletin of the*  
647 *World Health Organization* **61**, 383–94 (2014).
  - 648 2. Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P. & Hall-Stoodley, L. Targeting  
649 microbial biofilms: current and prospective therapeutic strategies. *Nat. Rev.*  
650 *Microbiol.* **15**, 740 (2017).
  - 651 3. Levin-Reisman, I. *et al.* Antibiotic tolerance facilitates the evolution of  
652 resistance. *Science* **355**, 826–830 (2017).
  - 653 4. Ahlgren, H. G. *et al.* Clinical outcomes associated with *Staphylococcus aureus*  
654 and *Pseudomonas aeruginosa* airway infections in adult cystic fibrosis  
655 patients. *BMC Pulm. Med.* **15**, 67 (2015).
  - 656 5. Serra, R. *et al.* Chronic wound infections: the role of *Pseudomonas aeruginosa*  
657 and *Staphylococcus aureus*. *Expert Rev. Anti. Infect. Ther.* **13**, 605–613  
658 (2015).
  - 659 6. Phalak, P., Chen, J., Carlson, R. P. & Henson, M. A. Metabolic modeling of a  
660 chronic wound biofilm consortium predicts spatial partitioning of bacterial  
661 species. *BMC Syst. Biol.* **10**, 90 (2016).
  - 662 7. Mashburn, L. M., Jett, A. M., Akins, D. R. & Whiteley, M. *Staphylococcus*  
663 *aureus* serves as an iron source for *Pseudomonas aeruginosa* during in vivo  
664 coculture. *J. Bacteriol.* **187**, 554–566 (2005).
  - 665 8. Limoli, D. H. *et al.* *Pseudomonas aeruginosa* alginate overproduction promotes  
666 coexistence with *Staphylococcus aureus* in a model of cystic fibrosis  
667 respiratory infection. *MBio* **8**, e00186-17 (2017).

- 668 9. Filkins, L. M. *et al.* Coculture of *Staphylococcus aureus* with *Pseudomonas*  
669 *aeruginosa* drives *S. aureus* towards fermentative metabolism and reduced  
670 viability in a cystic fibrosis model. *J. Bacteriol.* **197**, 2252–2264 (2015).
- 671 10. DeLeon, S. *et al.* Synergistic interactions of *Pseudomonas aeruginosa* and  
672 *Staphylococcus aureus* in an *in vitro* wound model. *Infect. Immun.* **82**, 4718–  
673 4728 (2014).
- 674 11. Duignan, C. M. Influence of low-dose nitric oxide on mono- and mixed-species  
675 biofilms formed by bacteria isolated from cystic fibrosis patients. (University of  
676 Southampton, 2017).
- 677 12. Hu, Y., Shamaei-Tousi, A., Liu, Y. & Coates, A. A new approach for the  
678 discovery of antibiotics by targeting non-multiplying bacteria: A novel topical  
679 antibiotic for Staphylococcal infections. *PLoS One* **5**, e11818 (2010).
- 680 13. Howlin, R. P. *et al.* Antibiotic-loaded synthetic calcium sulfate beads for  
681 prevention of bacterial colonization and biofilm formation in periprosthetic  
682 infections. *Antimicrob. Agents Chemother.* **59**, 111–120 (2015).
- 683 14. Foster, P. L. Methods for determining spontaneous mutation rates. *Methods*  
684 *Enzymol.* **409**, 195–213 (2006).
- 685 15. Hall, B. M., Ma, C. X., Liang, P. & Singh, K. K. Fluctuation anaLysis calculator:  
686 A web tool for the determination of mutation rate using Luria-Delbück  
687 fluctuation analysis. *Bioinformatics* **25**, 1564–1565 (2009).
- 688 16. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Unicycler: resolving  
689 bacterial genome assemblies from short and long sequencing reads. *PLOS*  
690 *Comput. Biol.* **13**, e1005595 (2017).
- 691 17. Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **30**,  
692 2068–2069 (2014).
- 693 18. Overbeek, R. *et al.* The SEED and the Rapid Annotation of microbial genomes  
694 using Subsystems Technology (RAST). *Nucleic Acids Res.* **42**, D206-14  
695 (2014).
- 696 19. Aziz, R. K. *et al.* The RAST Server: Rapid Annotations using Subsystems  
697 Technology. *BMC Genomics* **9**, 75 (2008).
- 698 20. Zheng, Q. New algorithms for Luria-Delbrück fluctuation analysis. *Math. Biosci.*  
699 **196**, 198–214 (2005).
- 700 21. Heydorn, A. *et al.* Quantification of biofilm structures by the novel computer  
701 program. *Image Process.* **146**, 2395–2407 (2000).

- 702 22. MacGregor-Fors, I. & Payton, M. E. Contrasting diversity values: statistical  
703 inferences based on overlapping confidence intervals. *PLoS One* **8**, e56794  
704 (2013).
- 705 23. Zheng, Q. Methods for comparing mutation rates using fluctuation assay data.  
706 *Mutat. Res. - Fundam. Mol. Mech. Mutagen.* **777**, 20–22 (2015).
- 707 24. Hunter, R. C. *et al.* Ferrous Iron Is a Significant Component of Bioavailable  
708 Iron in Cystic Fibrosis Airways. *MBio* **4**, e00557-13-e00557-13 (2013).
- 709 25. Tyrrell, J. & Callaghan, M. Iron acquisition in the cystic fibrosis lung and  
710 potential for novel therapeutic strategies. *Microbiology* **162**, 191–205 (2016).
- 711 26. Noinaj, N., Guillier, M., Barnard, T. J. & Buchanan, S. K. TonB-dependent  
712 transporters: regulation, structure, and function. *Annu. Rev. Microbiol.* **64**, 43–  
713 60 (2010).
- 714 27. Baldan, R. *et al.* Adaptation of *Pseudomonas aeruginosa* in cystic fibrosis  
715 airways influences virulence of *Staphylococcus aureus in vitro* and murine  
716 models of co-Infection. *PLoS One* **9**, e89614 (2014).
- 717 28. Palmer, K. L., Mashburn, L. M., Singh, P. K. & Whiteley, M. Cystic fibrosis  
718 sputum supports growth and cues key aspects of *Pseudomonas aeruginosa*  
719 physiology. *J. Bacteriol.* **187**, 5267–77 (2005).
- 720 29. Seth, A. K. *et al.* Comparative analysis of single-species and polybacterial  
721 wound biofilms using a quantitative, *in vivo*, rabbit ear model. *PLoS One* **7**,  
722 e42897 (2012).
- 723 30. Miller, C. L. *et al.* Global transcriptome responses including small RNAs during  
724 mixed-species interactions with methicillin-resistant *Staphylococcus aureus*  
725 and *Pseudomonas aeruginosa*. *Microbiologyopen* **6**, 1–22 (2017).
- 726 31. Nguyen, A. T. & Oglesby-Sherrouse, A. G. Spoils of war: iron at the crux of  
727 clinical and ecological fitness of *Pseudomonas aeruginosa*. *BioMetals* **28**,  
728 433–443 (2015).
- 729 32. Whittaker, J. W. Non-heme manganese catalase--the 'other' catalase. *Arch.*  
730 *Biochem. Biophys.* **525**, 111–20 (2012).
- 731 33. Liu, M., Zhang, Y., Inouye, M. & Woychik, N. A. Bacterial addiction module  
732 toxin Doc inhibits translation elongation through its association with the 30S  
733 ribosomal subunit. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 5885–90 (2008).
- 734 34. Ryder, V. J., Chopra, I. & O'Neill, A. J. Increased mutability of *Staphylococci* in  
735 biofilms as a consequence of oxidative stress. *PLoS One* **7**, e47695 (2012).

- 736 35. Driffield, K., Miller, K., Bostock, J. M., O’neill, A. J. & Chopra, I.  
737 Increased mutability of *Pseudomonas aeruginosa* in biofilms. *J. Antimicrob.*  
738 *Chemother.* **61**, 1053–1056 (2008).
- 739 36. Tognon, M. *et al.* Co-evolution with *Staphylococcus aureus* leads to  
740 lipopolysaccharide alterations in *Pseudomonas aeruginosa*. *ISME J.* **11**, 2233–  
741 2243 (2017).
- 742 37. Beaudoin, T. *et al.* *Staphylococcus aureus* interaction with *Pseudomonas*  
743 *aeruginosa* biofilm enhances tobramycin resistance. *npj Biofilms Microbiomes*  
744 **3**, 25 (2017).
- 745 38. Radlinski, L. *et al.* *Pseudomonas aeruginosa* exoproducts determine antibiotic  
746 efficacy against *Staphylococcus aureus*. *PLOS Biol.* **15**, e2003981 (2017).
- 747 39. Hubbard, A. T. M. *et al.* Mechanism of action of a membrane-active quinoline-  
748 based antimicrobial on natural and model bacterial membranes. *Biochemistry*  
749 **56**, 1163–1174 (2017).
- 750 40. Orazi, G. & O’Toole, G. A. *Pseudomonas aeruginosa* alters *Staphylococcus*  
751 *aureus* sensitivity to vancomycin in a biofilm model of cystic fibrosis infection.  
752 *MBio* **8**, e00873-17 (2017).
- 753 41. Lebeaux, D., Chauhan, A., Rendueles, O. & Beloin, C. From *in vitro* to *in vivo*  
754 models of bacterial biofilm-related infections. *Pathog. (Basel, Switzerland)* **2**,  
755 288–356 (2013).
- 756 42. Walker, W. T. *et al.* Primary ciliary dyskinesia ciliated airway cells show  
757 increased susceptibility to *Haemophilus influenzae* biofilm formation. *Eur.*  
758 *Respir. J.* **50**, 1700612 (2017).
- 759 43. Harrison, F. & Diggle, S. P. An *ex vivo* lung model to study bronchioles  
760 infected with *Pseudomonas aeruginosa* biofilms. *Microbiology* **162**, 1755–1760  
761 (2016).
- 762 44. Alves, P. M. *et al.* Interaction between *Staphylococcus aureus* and  
763 *Pseudomonas aeruginosa* is beneficial for colonisation and pathogenicity in a  
764 mixed biofilm. *Pathog. Dis.* **76**, (2018).
- 765